16P. Lollarture and function of porcine factor Xa-activated factorVIII. Biochemistry 1997;36:9365-73.16. Kasper CK, Aledort LM, Counts RB, Edson JR, FrantatoniJ, Gree D, et al. A more uniform measurement of factorVIII inhibitors. Thromb Diathes Haemorrh 1975; 34:869-72.17. Verbruggen B, Novakova I, Wessels H, Boezeman J, vanden Berg M, Mauser-Bunschoten E. The Nijmegen modificationof the Bethesda assay for factor VIII:Cinhibitors: improved specificity and reliability. ThrombHaemost 1995;73:247-51.18. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinantfactor VIII for the treatment of previouslyuntreated patients with hemophilia A. Safety, efficacy,and development of inhibitors. Kogenate PreviouslyUntreated Patient Study Group. N Engl J Med 1993; 328:453-9.19. Kessler CM, Ludlam CA. The treatment of acquired factorVIII inhibitors: worldwide experience with porcinefactor VIII concentrate. International Acquired HemophiliaStudy Group. Semin Hematol 1993;30:22-7.20. Biggs R, Austen DE, Denson KW, Borrett R, Rizza CR.The mode of action of antibodies which destroy factorVIII. II. Antibodies which give complex concentrationgraphs. Br J Haematol 1972;23:137-55.21. Biggs R, Austen DE, Denson KW, Rizza CE, Borrett R. Themode of action of antibodies which destroy factor VIII.I. Antibodies which have second-order concentrationgraphs. Br J Haematol 1972;23:125-35.22. Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulantactivity by two different types of human antibodies.Blood 1982;60:1103-9.23. Fulcher CA, Mahoney SD, Roberts JR, Kasper CK, ZimmermanTS. Localization of human factor FVIII inhibitorepitopes to two polypeptide fragments. Proc Natl AcadSci USA 1985;82:7728-32.24. Scandella D, Mahoney SD, Mattingly M, Roeder D, TimmonsL, Fulcher CA. Epitope mapping of human factorVIII inhibitor antibodies by deletion analysis of factorVIII fragments expressed in Escherichia Coli. Proc NatlAcad Sci USA 1988;85:6152-6.25. Scandella D, Mattingly M, de Graaf S, Fulcher CA. Localizationof epitopes for human factor VIII inhibitor antibodiesby immunoblotting and antibody neutralization.Blood 1989;74:1618-26.26. Scandella D, Timmons L, Mattingly M, Trabold N, HoyerLW. A soluble recombinant factor VIII fragment containingthe A2 domain binds to some human anti-factorVIII antibodies that are not detected by immunoblotting.Thromb Haemost 1992;67:665-71.27. Scandella D, Mattingly M, Prescott R. A recombinantfactor VIII A2 domain polypeptide quantitatively neutralizeshuman inhibitor antibodies which bind to A2.Blood 1993;82:1767-75.28. Prescott R, Nakai H, Saenko EL, Scharrer I, Nilsson IM,Humphries JE. The inhibitor antibody response is morecomplex in hemophilia A patients than in most nonhemophiliacswith factor VIII autoantibodies. Recombinateand Kogenate Study Groups. Blood 1997;89:3663-71.29. Duffy EJ, Parker ET, Mutucumarana VP, Johnson AE,Lollar P. Binding of factor VIIIa and factor VIII to factorIXa on phospholipid vesicles. J Biol Chem 1992; 267:17006-11.30. Bloom JW. The interaction of rDNA factor VIII, factorVIIIses-797-1562, and factor VIIIses-797-1562-derivedpeptides with phospholipid. Thromb Res 1987;48:439-48.31. Lollar P, Parke R, Curtis JE, Helgerson SL, Hoyer LW,Scott ME, Scandella D. Inhibition of human factor VII-Ia by anti-A2 subunit antibodies. J Clin Invest 1994; 93:2497-504.32. Fay PJ, Scandella D. Human inhibitor antibodies specificfor the factor VIII A2 domain disrupt the interactionbetween the subunit and factor IXa. J Biol Chem 1999;274:29826-30.33. Arai M, Scandella D, Hoyer LW. Molecular basis of factorVIII inhibition by human antibodies. Antibodies thatbind to the factor VIII light chain prevent the interactionof factor VIII with phospholipid. J Clin Invest 1989;83:1978-84.34. Saenko EL, Scandella D. The acidic region of the factorVIII light chain and the C2 domain together form thehigh affinity binding site for von Willebrand factor. JBiol Chem 1997;272:18007-14.35. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. Arole for the C2 domain of factor binding to von Willebrandfactor. J Biol Chem 1994;269:11601-5.36. Shima M, Nakai H, Scandella D, Tanaka I, Sawamoto Y,Kamisue S, et al. Common inhibitory effects of humananti-C2 domain inhibitor alloantibodies on factor VIIIbinding to von Willebrand factor. Br J Haematol 1995;91:714-21.37. Healey JF, Barrow RT, Tamim HM, Lubin IM, Shima M,Scandella D, et al. Residues Glu2181-Val2243 contain amajor determinant of the inhibitory epitope in the C2domain of human factor VIII. Blood 1998;92:3701-9.38. Healey JF, Lubin IM, Nakai H, Saenko EL, Hoyer LW,Scandella D, et al. Residues 484-508 contain a majordeterminant of the inhibitory epitope in the A2 domainof human factor VIII. J Biol Chem 1995;270:14505-9.39. Lubin IM, Healey JF, Scandella D, Lollar P. Analysis ofthe human factor VIII A2 inhibitor epitope by alaninescanning mutagenesis. J Biol Chem 1997;272:30191-5.40. Pratt KP, Shen BW, Takeshima K, Davie V, Fujikawa K,Stoddard BL. Structure of the C2 domain of human factorVIII at 1.5 A resolution. Nature 1999; 402:439-42.41. Jacquemin MG, Desqueper BG, Benhida A, Vander ElstL, Hoylaerts MF, Bakkus M, et al. Mechanism and kineticsof factor VIII inactivation: study with an IgG4 monoclonalantibody derived from a hemophilia A patientwith inhibitor. Blood 1998;92:496-506.42. Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I,Kamisue S, et al. A factor VIII neutralizing monoclonalantibody and a human inhibitor alloantibody recognizingepitopes in the C2 domain inhibit factor VIII bindingto von Willebrand factor and to phosphatidylserine.Thromb Haemost 1993;69:240-6.43. Spiegel PC Jr, Jacquemin M, Saint-Remy JM, StoddardBL, Pratt KP. Structure of the factor VIII C2 domainimmunoglobulinG4κ Fab complex: identification of aninhibitory antibody epitope on the surface of factor VIII.Blood 2001;98:13-9.44. Zhong D, Saenko EL, Shima M, Felch M, Scandella D.Some human inhibitor antibodies interfere with factorVIII binding to factor IX. Blood 1998;92:136-42.45. Lenting PJ, van de Loo JW, Donath MJ, van Mourik JA,Mertens K. The sequence Glu1811-Lys1818 of humanblood coagulation factor VIII comprises a binding sitefor activated factor IX. J Biol Chem 1996;271:1935-40.46. Barrow RT, Healey JF, Gailani D, Scandella D, Lollar P.Reduction of the antigenicity of factor VIII toward complexinhibitory plasmas using multiply-substitutedhybrid human/porcine factor VIII molecules. Blood2000; 95:557-61.47. Jacquemin M, Benhida A, Peerlinck K, Desqueper B,Vander EL, Lavend'homme R, et al. A human antibodydirected to the factor VIII C1 domain inhibits factor VIIIcofactor activity and binding to von Willebrand factor.Blood 2000;95:156-63.48. van den Brink EN, Timmermans SM, Turenhout EA,Bank CM, Fijnvandraat K, Voorberg J, et al. Longitudinalanalysis of factor VIII inhibitors in a previouslyuntreated mild haemophilia A patient with anArg593→Cys substitution. Thromb Haemost 1999; 81:723-6.49. Shibata M, Shima M, Morichika S, McVey J, TuddenhamEG, I. Tanaka H, et al. An alloantibody recognizingthe FVIII A1 domain in a patient with CRM reducedhaemophilia A due to deletion of a large portion of theA1 domain DNA sequence. Thromb Haemost 2000; 84:442-8.50. Nogami K, Shima M, Giddings JC, Hosokawa K, NagataM, Kamisue S, et al. Circulating factor VIII immunecomplexes in patients with type 2 acquired hemophiliaA and protection from activated protein C-mediated proteolysis.Blood 2001;97:669-77.51. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, RaoAV, Lazerson J. The natural history of factor VIII:Cinhibitors in patients with hemophilia A: a national cooperativestudy. II. Observations on the initial developmentof factor VIII:C inhibitors. Blood 1988;71:344-8.haematologica vol. 88(supplement n. 12):september <strong>2003</strong>
IV International Workshop on Immune Tolerance in Hemophilia 1752. Sawamoto Y, Prescott R, Zhong D, Saenko EL, Mauser-Bunschoten E, Peerlinek K, et al. C2 domain restrictedepitope specificity of inhibitor antibodies elicited by aheat pasteurized product, factor VIII CPS-P, in previouslytreated hemophilia A patients without inhibitors.Thromb Haemost 1998;79:62-8.53. Laub R, Di Giambattista M, Fondu P, Brackmann HH,Lenk H, Saenko EL, et al. Inhibitors in German hemophiliaA patients treated with a double virus inactivatedfactor VIII concentrate bind to the C2 domain of FVIIIlight chain.\par. Thromb Haemost 1999;81:39-44.54. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD,Kazazian Jr HH. Targeted disruption of the mouse factorVIII gene produces a model of haemophilia A. Nat Genet1995;10:119-21.55. Sarkar R, Gao GP, Chirmule N, Tazelaar J, Kazazian HHJr. Partial correction of murine hemophilia A with neoantigenicmurine factor VIII. Hum Gene Ther 2000; 11:881-94.56. Qian J, M Borovak, Bi L, Kazazian Jr HH, Hoyer L.Inhibitor antibody development and T cell response tohuman factor VIII in murine hemophilia A. ThrombHaemost 1999;81:240-4.57. Wu H, Reding M, Qian J, Okita DK, Parker E, Lollar P,et al. Mechanism of the immune response to humanfactor VIII in murine hemophilia A. Thromb Haemost2001;85:125-33.58. Reding MT, Wu H, Krampf M, Okita DK, Diethelm-OkitaBM, Christie BA, et al. Sensitization of CD4 + T cells tocoagulation factor VIII: response in congenital andacquired hemophilia patients and in healthy subjects.Thromb Haemost 2000;84:643-52.59. Qian J, Collins M, Sharpe AM, Hoyer LW. Preventionand treatment of factor VIII inhibitors in murine hemophiliaA. Blood 2000;95:1324-9.60. Rossi G, Sarkar J, Scandella D. Long-term induction ofimmune tolerance after blockade of CD40-CD40L interactionin a mouse model of hemophilia A. Blood 2001;97:2750-7.61. Qian J, Burkly LC, Smith EP, Ferrant JL, Hoyer LW, ScottDW, Haudenschild CC. Role of CD154 in the secondaryimmune response: the reduction of pre-existing splenicgerminal centers and anti-factor VIII inhibitor titer. EurJ Immunol 2000;30:2548-54.62. Balague C, Zhou J, Dai Y, Alemany R, Josephs SF,Andreason G, et al. Sustained high-level expression offull-length human factor VIII and restoration of clottingactivity in hemophilic mice using a minimal adenovirusvector. Blood 2000;95:820-8.63. Connelly S, Andrews JL, Gallo AM, Kayda DM, Qian J,Hoyer L, et al. Sustained phenotypic correction ofmurine hemophilia A by in vivo gene therapy. Blood1998;91:3273-81.64. Evans GL, Morgan RA. Genetic induction of immunetolerance to human clotting factor VIII in a mouse modelfor hemophilia A. Proc Natl Acad Sci USA 1998; 95:5734-9.haematologica vol. 88(supplement n. 12):september <strong>2003</strong>
Change language